Savannah R Smith1, Jeffrey N Katz2, Jamie E Collins2, Daniel H Solomon3, Joanne M Jordan4, Lisa G Suter5, Edward H Yelin6, A David Paltiel7, Elena Losina2. 1. Orthopaedic and Arthritis Center for Outcomes Research and Brigham and Women's Hospital, Boston, Massachusetts. 2. Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts. 3. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 4. University of North Carolina, Chapel Hill. 5. Yale University, New Haven, and Veterans Affairs Medical Center, West Haven, Connecticut. 6. University of California, San Francisco. 7. Yale University, New Haven, Connecticut.
Abstract
OBJECTIVE: To evaluate the cost-effectiveness of incorporating tramadol or oxycodone into knee osteoarthritis (OA) treatment. METHODS: We used the Osteoarthritis Policy Model to evaluate long-term clinical and economic outcomes of knee OA patients with a mean age of 60 years with persistent pain despite conservative treatment. We evaluated 3 strategies: opioid-sparing (OS), tramadol (T), and tramadol followed by oxycodone (T+O). We obtained estimates of pain reduction and toxicity from published literature and annual costs for tramadol ($600) and oxycodone ($2,300) from Red Book Online. Based on published data, in the base case, we assumed a 10% reduction in total knee arthroplasty (TKA) effectiveness in opioid-based strategies. Outcomes included quality-adjusted life years (QALYs), lifetime cost, and incremental cost-effectiveness ratios (ICERs) and were discounted at 3% per year. RESULTS: In the base case, T and T+O strategies delayed TKA by 7 and 9 years, respectively, and led to reduction in TKA utilization by 4% and 10%, respectively. Both opioid-based strategies increased cost and decreased QALYs compared to the OS strategy. Tramadol's ICER was highly sensitive to its effect on TKA outcomes. Reduction in TKA effectiveness by 5% (compared to base case 10%) resulted in an ICER for the T strategy of $110,600 per QALY; with no reduction in TKA effectiveness, the ICER was $26,900 per QALY. When TKA was not considered a treatment option, the ICER for T was $39,600 per QALY. CONCLUSION: Opioids do not appear to be cost-effective in OA patients without comorbidities, principally because of their negative impact on pain relief after TKA. The influence of opioids on TKA outcomes should be a research priority.
OBJECTIVE: To evaluate the cost-effectiveness of incorporating tramadol or oxycodone into knee osteoarthritis (OA) treatment. METHODS: We used the Osteoarthritis Policy Model to evaluate long-term clinical and economic outcomes of knee OA patients with a mean age of 60 years with persistent pain despite conservative treatment. We evaluated 3 strategies: opioid-sparing (OS), tramadol (T), and tramadol followed by oxycodone (T+O). We obtained estimates of pain reduction and toxicity from published literature and annual costs for tramadol ($600) and oxycodone ($2,300) from Red Book Online. Based on published data, in the base case, we assumed a 10% reduction in total knee arthroplasty (TKA) effectiveness in opioid-based strategies. Outcomes included quality-adjusted life years (QALYs), lifetime cost, and incremental cost-effectiveness ratios (ICERs) and were discounted at 3% per year. RESULTS: In the base case, T and T+O strategies delayed TKA by 7 and 9 years, respectively, and led to reduction in TKA utilization by 4% and 10%, respectively. Both opioid-based strategies increased cost and decreased QALYs compared to the OS strategy. Tramadol's ICER was highly sensitive to its effect on TKA outcomes. Reduction in TKA effectiveness by 5% (compared to base case 10%) resulted in an ICER for the T strategy of $110,600 per QALY; with no reduction in TKA effectiveness, the ICER was $26,900 per QALY. When TKA was not considered a treatment option, the ICER for T was $39,600 per QALY. CONCLUSION: Opioids do not appear to be cost-effective in OA patients without comorbidities, principally because of their negative impact on pain relief after TKA. The influence of opioids on TKA outcomes should be a research priority.
Authors: Elena Losina; A David Paltiel; Alexander M Weinstein; Edward Yelin; David J Hunter; Stephanie P Chen; Kristina Klara; Lisa G Suter; Daniel H Solomon; Sara A Burbine; Rochelle P Walensky; Jeffrey N Katz Journal: Arthritis Care Res (Hoboken) Date: 2015-02 Impact factor: 4.794
Authors: Elena Losina; Rochelle P Walensky; William M Reichmann; Holly L Holt; Hanna Gerlovin; Daniel H Solomon; Joanne M Jordan; David J Hunter; Lisa G Suter; Alexander M Weinstein; A David Paltiel; Jeffrey N Katz Journal: Ann Intern Med Date: 2011-02-15 Impact factor: 25.391
Authors: T E McAlindon; R R Bannuru; M C Sullivan; N K Arden; F Berenbaum; S M Bierma-Zeinstra; G A Hawker; Y Henrotin; D J Hunter; H Kawaguchi; K Kwoh; S Lohmander; F Rannou; E M Roos; M Underwood Journal: Osteoarthritis Cartilage Date: 2014-01-24 Impact factor: 6.576
Authors: Ronald C Wielage; Megha Bansal; J Scott Andrews; Robert W Klein; Michael Happich Journal: Appl Health Econ Health Policy Date: 2013-06 Impact factor: 2.561
Authors: Reva C Lawrence; David T Felson; Charles G Helmick; Lesley M Arnold; Hyon Choi; Richard A Deyo; Sherine Gabriel; Rosemarie Hirsch; Marc C Hochberg; Gene G Hunder; Joanne M Jordan; Jeffrey N Katz; Hilal Maradit Kremers; Frederick Wolfe Journal: Arthritis Rheum Date: 2008-01
Authors: J N Katz; S R Smith; J E Collins; D H Solomon; J M Jordan; D J Hunter; L G Suter; E Yelin; A D Paltiel; E Losina Journal: Osteoarthritis Cartilage Date: 2015-10-23 Impact factor: 6.576
Authors: Savannah R Smith; Jennifer Bido; Jamie E Collins; Heidi Yang; Jeffrey N Katz; Elena Losina Journal: J Bone Joint Surg Am Date: 2017-05-17 Impact factor: 5.284
Authors: Angela T Chen; Corin I Bronsther; Elizabeth E Stanley; A David Paltiel; James K Sullivan; Jamie E Collins; Tuhina Neogi; Jeffrey N Katz; Elena Losina Journal: Ann Intern Med Date: 2021-03-23 Impact factor: 25.391
Authors: Nora K Lenhard; James K Sullivan; Eric L Ross; Shuang Song; Robert R Edwards; David J Hunter; Tuhina Neogi; Jeffrey N Katz; Elena Losina Journal: Arthritis Care Res (Hoboken) Date: 2022-03-29 Impact factor: 5.178
Authors: Jamie L Huizinga; Elizabeth E Stanley; James K Sullivan; Shuang Song; David J Hunter; A David Paltiel; Tuhina Neogi; Robert R Edwards; Jeffrey N Katz; Elena Losina Journal: Arthritis Care Res (Hoboken) Date: 2022-05-10 Impact factor: 5.178
Authors: J K Sullivan; J Huizinga; R R Edwards; D J Hunter; T Neogi; E Yelin; J N Katz; E Losina Journal: Osteoarthritis Cartilage Date: 2020-11-07 Impact factor: 6.576
Authors: Codie A Primeau; Bryn O Zomar; Lyndsay E Somerville; Ishita Joshi; J Robert Giffin; Jacquelyn D Marsh Journal: Orthop J Sports Med Date: 2021-03-09